title: Enzyme-coated mesoporous silica nanoparticles as efficient antibacterial agents in vivo.
abstract: Despite the fact that pathogenic infections are widely treated by antibiotics in the clinic nowadays, the increasing risk of multidrug-resistance associated with abuse of antibiotics is becoming a major concern in global public health. The increased death toll caused by pathogenic bacterial infection calls for effective antibiotic alternatives. Lysozyme-coated mesoporous silica nanoparticles (MSNs⊂Lys) are reported as antibacterial agents that exhibit efficient antibacterial activity both in vitro and in vivo with low cytotoxicity and negligible hemolytic side effect. The Lys corona provides multivalent interaction between MSNs⊂Lys and bacterial walls and consequently raises the local concentration of Lys on the surface of cell walls, which promotes hydrolysis of peptidoglycans and increases membrane-perturbation abilities. The minimal inhibition concentration (MIC) of MSNs⊂Lys is fivefold lower than that of free Lys in vitro. The antibacterial efficacy of MSNs⊂Lys is evaluated in vivo by using an intestine-infected mouse model. Experimental results indicate that the number of bacteria surviving in the colon is three orders of magnitude lower than in the untreated group. These natural antibacterial enzyme-modified nanoparticles open up a new avenue for design and synthesis of next-generation antibacterial agents as alternatives to antibiotics.
authors.affiliation: Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, No. 11 Beiyitiao, Zhongguancun, Beijing, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Li
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004800:Enzymes, Immobilized / Q000737:chemistry / Q000378:metabolism; D004926:Escherichia coli / Q000187:drug effects / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology; D016650:Fluorescein-5-isothiocyanate / Q000737:chemistry; D057809:HEK293 Cells; D006461:Hemolysis; D006801:Humans; D007422:Intestines / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D018613:Microscopy, Confocal; D009113:Muramidase / Q000737:chemistry / Q000378:metabolism*; D053758:Nanoparticles / Q000737:chemistry* / Q000627:therapeutic use / Q000633:toxicity; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry*
chemical_list: D000900:Anti-Bacterial Agents; D004800:Enzymes, Immobilized; D012822:Silicon Dioxide; D009113:Muramidase; D016650:Fluorescein-5-isothiocyanate
keywords: antibacterial agents; lysozyme; mesoporous silica nanoparticles (MSNs)